James Terwilliger analyst

Currently out of the existing stock ratings of James Terwilliger, 15 are a BUY (75%), 5 are a HOLD (25%).

James Terwilliger

Work Performance Price Targets & Ratings Chart

Analyst James Terwilliger, currently employed carries an average stock price target met ratio of 48% that have a potential upside of 29.55% achieved within 321 days.

James Terwilliger’s has documented 43 price targets and ratings displayed on 5 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on INFU, InfuSystems Holdings at 29-Dec-2021.

Wall Street Analyst James Terwilliger

Analyst best performing recommendations are on ZYXI (ZYNEX).
The best stock recommendation documented was for ZYXI (ZYNEX) at 4/1/2020. The price target of $13.64 was fulfilled within 26 days with a profit of $3.81 (38.76%) receiving and performance score of 14.91.

Average potential price target upside

CSII Cardiovascular Systems HCSG Healthcare Services Group SRTS Sensus Healthcare ZYXI Zynex INFU InfuSystems Holdings

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$25

$5 (25.00%)

$48

1 years 11 months 3 days ago
(14-Dec-2022)

4/8 (50%)

$10.95 (77.94%)

512

Hold

$18

$-2 (-10.00%)

$32

2 years 5 months 9 days ago
(08-Jun-2022)

3/4 (75%)

$2.82 (18.58%)

194

Buy

$20

$20

2 years 6 months 12 days ago
(05-May-2022)

12/13 (92.31%)

$4.32 (27.55%)

430

Buy

$34

$14 (70.00%)

$34

2 years 7 months 19 days ago
(29-Mar-2022)

1/5 (20%)

$11.85 (53.50%)

295

Hold

$49

2 years 11 months 30 days ago
(18-Nov-2021)

9/11 (81.82%)

$15.66 (46.97%)

234

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by James Terwilliger?

On 2013

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?